- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02862054
Splenectomy as a Treatment for Patient With Relapsed Haemophagocytic Lymphohistiocytosis of Unknown Etiology
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Anticipated)
Phase
- Phase 2
- Phase 3
Contacts and Locations
Study Locations
-
-
Beijing
-
Beijing, Beijing, China, 100050
- Recruiting
- Beijing Friendship Hospital, Capital Medical University
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Patients were older than 14 years of age
- Diagnosed as Hemophagocytic Lymphohistiocytosis (HLH) according to HLH-2004.
- patients were excluded with infection, rheumatic and immunologic diseases, malignant tumors (especially lymphoma), and primary HLH.
- Informed consent
Exclusion Criteria:
- Pregnancy or lactating Women
- Active bleeding of the internal organs
- Uncontrollable infection
- Contraindication of splenectomy
- Participate in other clinical research at the same time
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: NA
- Interventional Model: SINGLE_GROUP
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Splenectomy
Splenectomy as a treatment for patient with relapsed haemophagocytic lymphohistiocytosis of unknown etiology
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Evaluation of treatment response
Time Frame: Change from before and1,2,4,8,12 and 24 weeks after splenectomy
|
A complete response was defined as normalization of all of the quantifiable symptoms and laboratory markers of HLH, including levels of sCD25, ferritin, and triglyceride; hemoglobin; neutrophil counts; platelet counts; and alanine aminotransferase (ALT). A partial response was defined as at least a 25% improvement in 2 or more quantifiable symptoms and laboratory markers as follows: sCD25 response was>1.5-fold decreased; ferritin and triglyceride decreased at least 25%; for patients with an initial neutrophil count of<0.5 ×109/L, a response was defined as an increase by at least 100% to>0.5× 109/L; for patients with a neutrophil count of 0.5 to 2.0 × 109/L, an increase by at least 100% to >2.0 × 109/L was considered a response; and for patients with ALT >400 U/L, response was defined as an ALT decrease of at least 50%. |
Change from before and1,2,4,8,12 and 24 weeks after splenectomy
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Survival
Time Frame: from the time patients received splenectomy up to 24 months or December 2018
|
from the time patients received splenectomy up to 24 months or December 2018
|
|
Adverse events that are related to treatment
Time Frame: through study completion, an average of 2 years
|
Adverse events including infection, bleeding and so on.
|
through study completion, an average of 2 years
|
Collaborators and Investigators
Sponsor
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (ANTICIPATED)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ESTIMATE)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- Splenectomy-HLH
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hemophagocytic Lymphohistiocytosis
-
The First Affiliated Hospital with Nanjing Medical...Unknown
-
Assistance Publique - Hôpitaux de ParisCompleted
-
University of California, San FranciscoIncyte CorporationNot yet recruitingRuxolitinib With De-Intensified HLH-94 for the Treatment of Hemophagocytic Lymphohistiocytosis (HLH)Hemophagocytic LymphohistiocytosesUnited States
-
Children's Hospital Medical Center, CincinnatiBaylor College of Medicine; Sobi, Inc.RecruitingHemophagocytic LymphohistiocytosesUnited States
-
Swedish Orphan BiovitrumLight Chain Bioscience - Novimmune SATerminatedHemophagocytic LymphohistiocytosesUnited States
-
Swedish Orphan BiovitrumHarvard Medical School (HMS and HSDM); Brigham and Women's HospitalCompletedHemophagocytic LymphohistiocytosesUnited States
-
Beijing Friendship HospitalNot yet recruitingEBV | Hemophagocytic Lymphohistiocytoses | MetabonomicsChina
-
Beijing Friendship HospitalUnknownHemophagocytic LymphohistiocytosisChina
-
Beijing Friendship HospitalRecruitingHemophagocytic LymphohistiocytosisChina
-
St. Jude Children's Research HospitalIncyte Corporation; North American Consortium for Histiocytosis; Cures Within...RecruitingHemophagocytic LymphohistiocytosisUnited States
Clinical Trials on splenectomy
-
Children's Mercy Hospital Kansas CityWithdrawnIdiopathic Thrombocytopenic Purpura | Hereditary SpherocytosisUnited States
-
Yonsei UniversityTerminatedDuctal Adenocarcinoma | Left-sided Pancreatic CancerKorea, Republic of
-
Zhang LeiRecruitingThrombocytopenia | SplenectomyChina
-
Zagazig UniversityCompletedLaparoscopic Surgery
-
First Affiliated Hospital of Harbin Medical UniversityUnknownInfection | Gut Microbiota | Spleen InjuryChina
-
Tanta UniversityCompletedChildren | Laparoscopic Splenectomy | Benign Blood Diseases
-
Tecnologico de MonterreyCompletedArterial Splenic AneurysmMexico
-
Northern Jiangsu People's HospitalRecruitingCirrhosis, Liver | Splenectomy; StatusChina
-
Haruhiko FukudaMinistry of Health, Labour and Welfare, JapanCompleted
-
University of Illinois at ChicagoCompletedPediatric Robotic SurgeryUnited States